Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors

NCT01056029 is registered in ClinicalTrials.gov with GenSpera, Inc. as lead sponsor.

NCT NCT01056029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01056029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
Lead sponsor
GenSpera, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2010
Completion date
August 31, 2013
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors